BenevolentAI Investor Presentation Deck
BenevolentAl business model
Al-Discovery Tools
D
Target
Identification
ООО
Precision
Medicine
°C
0 0 0
i
Knowledge
Molecular
Design
In-house pipeline of
novel discovery-stage
assets
Platform Collaborations:
Selective platform collaborations which
can leverage the BenevolentAl
PlatformTM in areas outside our core
competencies
Non-commercial Collaborations (DNDI, COVID-19)
Economic
benefits
A
B
ESG
BenevolentAl develop
and commercialise
Out-licence at IND, end
Phase I or end Phase II
(upfront, milestones, royalties)
Platform
validation
Platform
validation
Decision Criteria:
• Feasibility of mid and
late stage clinical
development (size,
specialism)
• Fit with emerging
commercialisation
model
• Funding environment
Data generated enriches the
BenevolentAl Platform™
Data generated enriches the
BenevolentAl Platform™
Benevolent
8View entire presentation